A composition with antibacterial activity, preparation method and application thereof

The sulfate polysaccharide coats the complex of isoquinoline alkaloids and flavonoid glycosides to form a nanostructure, which solves the problem of insufficient antibacterial activity of berberine, significantly improves its antibacterial effect, and provides support for the development of natural antibacterial drugs.

CN115177633BActive Publication Date: 2024-11-22PEKING UNION MEDICAL COLLEGE HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210571468.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-05-24
Publication Date
2024-11-22
Estimated Expiration
2042-05-24

AI Technical Summary

Technical Problem

The poor water solubility of berberine and its metabolism in the intestine cause its antibacterial effect to be weakened. The prior art has failed to effectively improve its antibacterial activity, especially the complex of berberine isoquinoline alkaloids and flavonoid glycosides through natural polysaccharides. The method has not been reported.

Method used

The complex of isoquinoline alkaloids and flavonoid glycosides is coated with sulfate polysaccharides, and nanocomposites are prepared by self-assembly of molecules to form nanostructures, improve their antibacterial activity, and the nanocomposites are prepared by specific preparation methods such as dissolution, mixing, heating and centrifugation. .

Benefits of technology

It significantly improves the dispersion, stability and bioavailability of berberine substances, enhances its antibacterial activity, and provides support for the research and development of new antibacterial drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003660428930000071
    Figure BDA0003660428930000071
  • Figure BDA0003660428930000081
    Figure BDA0003660428930000081
  • Figure BDA0003660428930000101
    Figure BDA0003660428930000101
Patent Text Reader

Abstract

The present invention provides a composition with antibacterial activity, comprising: (1) sulfated polysaccharide, and (2) a complex of isoquinoline alkaloid and flavonoid glycoside, wherein the sulfated polysaccharide covers the complex. The composition has high antibacterial activity and has a good inhibitory effect on Staphylococcus aureus, Salmonella enteritidis, Shigella flexneri and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of drug synthesis, and in particular to a composition with antibacterial activity, a preparation method thereof and application thereof. Background Art

[0002] Isoquinoline alkaloids have excellent antibacterial properties. Take berberine as an example. It is a natural four-membered isoquinoline with strong alkalinity found in herbs such as Phellodendron chinense and Coptis chinensis. It mostly exists in the form of hydrochloride, called berberine hydrochloride. It is a yellow needle-shaped crystal with a bitter taste. It has antibacterial, anti-allergic, anti-tumor and blood sugar lowering functions. At present, berberine is mainly used in the clinic to treat intestinal diseases such as bacterial diarrhea. However, due to its poor water solubility, it is difficult to absorb after oral administration and has low bioavailability in plasma. In addition, after berberine enters the intestine, it is converted into metabolites such as dihydroberberine by nitroreductase in intestinal bacteria, resulting in a weakening of its antibacterial effect. Flavonoid glycosides represented by baicalin in Scutellaria baicalensis also have clear antibacterial activity. Studies have shown that natural polysaccharides have biological functions of regulating the body's immune response and antibacterial, which are manifested in immunomodulatory activity, anti-inflammation, anti-tumor, anti-allergy, antiviral and other aspects.

[0003] Some studies have used nanotechnology to prepare berberine nanomedicine to improve its antibacterial efficacy. Other studies have shown that the complex of berberine and flavonoid glycosides can significantly improve the antibacterial activity of berberine, but there are no reports on the use of natural polysaccharides to encapsulate the complex of berberine isoquinoline alkaloids and flavonoid glycosides to further improve the antibacterial activity. Summary of the invention

[0004] The purpose of the present invention is to provide a composition with antibacterial activity and a preparation method thereof. The composition comprises a complex of isoquinoline alkaloid and flavonoid glycoside coated with sulfated polysaccharide. The composition has high antibacterial activity and can make the complex of sulfated polysaccharide, isoquinoline alkaloid and flavonoid glycoside produce a synergistic antibacterial effect, enhance its biological activity, and provide support for the research and development and application of new antibacterial drugs.

[0005] To achieve this object, the present invention adopts the following technical solutions:

[0006] The first aspect of the present invention provides a composition having antibacterial activity, comprising:

[0007] (1) sulfated polysaccharides, and

[0008] (2) Complexes of isoquinoline alkaloids and flavonoid glycosides,

[0009] The sulfated polysaccharide coats the complex.

[0010] According to some embodiments of the present invention, the sulfated polysaccharide is a red algae sulfated polysaccharide; preferably, the red algae is selected from Pyrophyta haitanensis, Gracilaria lemaneiformis and Eucheuma indica.

[0011] According to some embodiments of the present invention, the isoquinoline alkaloid is selected from berberine or a salt thereof, coptisine, palmatine, jatrorrhizine, epiberberine, phellodendronine and tetrahydropalmatine; preferably berberine or a salt thereof.

[0012] According to some embodiments of the present invention, the flavonoid glycoside is selected from baicalin, wogonin, scutellaria baicalensis and melaleuca alternifolia; preferably baicalin.

[0013] According to a preferred embodiment of the present invention, the composite has a nanostructure.

[0014] According to a preferred embodiment of the present invention, the complex is a nanoparticle formed by isoquinoline alkaloids and flavonoid glycosides. Preferably, the nanocomposite is a nanoparticle formed by isoquinoline alkaloids and flavonoid glycosides through molecular self-assembly. Molecular self-assembly is a type of stable molecular aggregate or supramolecular structure with certain specific functions or properties formed by non-covalent bond interactions or spontaneous combinations between molecules under equilibrium conditions.

[0015] According to some embodiments of the present invention, the ultraviolet spectrum of the composite has a maximum absorption peak at wavelengths of 315nm-345nm and 263nm-275nm respectively.

[0016] According to some embodiments of the present invention, the composite has a nanofiber structure, the diameter of the nanofiber is 1nm-50nm, each nanofiber is connected by a bead-like structure composed of small nanoparticles, and the nanofibers are interwoven to form a mesh structure.

[0017] According to some embodiments of the present invention, the composite is prepared by a method comprising the following steps:

[0018] (1) dissolving an isoquinoline alkaloid in a solvent A to obtain an isoquinoline alkaloid solution;

[0019] (2) dissolving the flavonoid glycoside in solvent B to obtain a flavonoid glycoside solution;

[0020] (3) Mixing the isoquinoline alkaloid solution with the flavonoid glycoside solution to obtain a complex of the isoquinoline alkaloid and the flavonoid glycoside.

[0021] According to some embodiments of the present invention, the solvent A is water, preferably ultrapure water.

[0022] According to some embodiments of the present invention, the solvent B is water, preferably ultrapure water.

[0023] According to some embodiments of the present invention, the molar ratio of the isoquinoline alkaloid to the flavonoid glycoside is 1:(0.1-10), for example 1:0.1, 1:0.5, 1:1, 1:2, 1:5, 1:10.

[0024] According to some embodiments of the present invention, the isoquinoline alkaloid solution and the flavonoid glycoside solution are mixed in a volume ratio of 1:(0.1-10), for example, 1:0.1, 1:0.5, 1:1, 1:2, 1:5, 1:10.

[0025] According to some embodiments of the present invention, the composite is prepared by a method comprising the following steps:

[0026] (1) dissolving berberine and baicalin in water respectively, and adjusting the pH of the baicalin aqueous solution to 8-12;

[0027] (2) The berberine aqueous solution and the baicalin aqueous solution are mixed, heated and stirred, and centrifuged to obtain a precipitate that is a nanocomposite of berberine and baicalin.

[0028] According to some embodiments of the present invention, the molar ratio of berberine to baicalin is 1:(0.1-10), for example 1:0.1, 1:0.5, 1:1, 1:2, 1:5, 1:10.

[0029] According to a preferred embodiment of the present invention, an organic base or an inorganic base is used to adjust the pH of the baicalin aqueous solution to 8-12. Preferably, the inorganic base is selected from sodium hydroxide, sodium bicarbonate and sodium carbonate.

[0030] According to some embodiments of the invention, the berberine aqueous solution and the baicalin aqueous solution are mixed in a volume ratio of 1:(0.1-10), for example, 1:0.1, 1:0.5, 1:1, 1:2, 1:5, 1:10.

[0031] According to some embodiments of the present invention, the heating temperature is 30°C-100°C, such as 30°C, 50°C, 80°C, 100°C, preferably 60°C-90°C.

[0032] According to some embodiments of the present invention, the stirring is magnetic stirring, and the time of the magnetic stirring is 20min-80min, for example 30min, 40min, 50min, 60min, 70min, 80min, preferably 40min-70min; the rotation speed of the magnetic stirring is 10-20, for example 10, 15, 20.

[0033] According to some embodiments of the present invention, the centrifugal rotation speed is 4000rpm-10000rpm, for example 4000rpm, 5000rpm, 6000rpm, 7000rpm, 8000rpm, 9000rpm, 10000rpm, preferably 7000rpm-9000rpm.

[0034] According to some embodiments of the present invention, the precipitate obtained by centrifugation is washed with ultrapure water to obtain the nanocomplex.

[0035] The second aspect of the present invention provides a method for preparing the composition, comprising the steps of:

[0036] (1) mixing a sulfated polysaccharide with a first solvent to form a sulfated polysaccharide solution;

[0037] (2) mixing the complex of isoquinoline alkaloid and flavonoid glycoside with a second solvent to form a complex solution of isoquinoline alkaloid and flavonoid glycoside;

[0038] (3) Mixing the sulfated polysaccharide solution with the complex solution of isoquinoline alkaloid and flavonoid glycoside.

[0039] According to some embodiments of the present invention, the first solvent is water, preferably ultrapure water.

[0040] According to some embodiments of the present invention, the second solvent is water, preferably ultrapure water.

[0041] According to some embodiments of the present invention, the concentration of the sulfated polysaccharide solution is 5 mg / mL-15 mg / mL, such as 5 mg / mL, 8 mg / mL, 10 mg / mL, 12 mg / mL, 15 mg / mL.

[0042] According to some embodiments of the present invention, the concentration of the complex solution of isoquinoline alkaloid and flavonoid glycoside is 2mmol / L-10mmol / L, such as 2mmol / L, 4mmol / L, 6mmol / L, 8mmol / L, 10mmol / L.

[0043] According to some embodiments of the present invention, the sulfated polysaccharide solution and the complex solution of isoquinoline alkaloid and flavonoid glycoside are mixed in a volume ratio of (1-3):1, such as 1:1, 2:1, 3:1.

[0044] The third aspect of the present invention provides use of the composition in preparing an antibacterial product.

[0045] According to some embodiments of the present invention, the product is a medicine and / or a health food.

[0046] According to some embodiments of the present invention, the medicament comprises the composition or a pharmaceutically acceptable salt thereof and an excipient.

[0047] According to some embodiments of the present invention, the excipient is selected from one or more of starch, magnesium stearate, hydroxypropylcellulose carboxyl, sodium methyl starch, talc, and sucrose.

[0048] According to some embodiments of the present invention, the dosage form of the drug is tablets, powders, granules, ointments, creams or capsules; preferably tablets, ointments, creams or capsules.

[0049] Compared with the prior art, the present invention has the following advantages: the present invention is based on nanotechnology to obtain a nanocomposite of isoquinoline alkaloids and flavonoid glycosides, and sulfated polysaccharides are used as the encapsulation material of the nanocomposite, which not only improves the dispersibility and stability of berberine-type small molecule active substances and improves bioavailability, but also further improves its antibacterial activity, and the raw materials are all natural ingredients with abundant sources and low costs, which can provide support for the development of more effective natural antibacterial drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0050] Figure 1 The scanning electron micrographs of the berberine / baicalin nanoparticles obtained in Example 1 and Example 2 are shown.

[0051] Figure 2 The sulfated polysaccharide solutions obtained in Example 1 and Example 2 are shown, (A) PHSP, (B) ESP.

[0052] Figure 3 The sulfated polysaccharide-coated berberine / baicalin nanoparticles obtained in Example 1 and Example 2 are shown, (A) NP1-PHSP, (B) NP1-ESP.

[0053] Figure 4 Scanning electron micrographs of the sulfated polysaccharides obtained in Example 1 and Example 2 are shown, (A) PHSP, (B) ESP.

[0054] Figure 5 Scanning electron micrographs of sulfated polysaccharide-coated berberine / baicalin nanoparticles obtained in Example 1 and Example 2 are shown, (A) NP1-PHSP, (B) NP1-ESP. DETAILED DESCRIPTION

[0055] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with embodiments. The specific embodiments described herein are only used to explain the present invention and are not intended to constitute any limitation to the present invention.

[0056] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly used in the art to which this invention belongs.

[0057] Example 1: Preparation and characterization of berberine / basicin complex nanoparticles coated with sulfated polysaccharide of Porphyra haitanensis

[0058] (1) Prepare berberine and baicalin aqueous solutions with a concentration of 2 mM each.

[0059] (2) A round-bottom flask containing 8.51 mL of baicalin (2 mM, pH = 10.0) and 8.51 mL of berberine (2 mM) was placed on a heat-collecting constant temperature magnetic stirrer at a speed of 20 rpm and heated at 80°C for 1 h. After centrifugation at 9000 r / min, the supernatant was discarded, and the precipitate was washed with ultrapure water for 3 times, and 4.25 mL of ultrapure water was added and mixed. The precipitate was berberine / baicalin complex nanoparticles (NP1). The nanoparticles showed a mesh-like nanofiber structure under a transmission electron microscope, and the diameter of the nanofibers was about 1 nm-50 nm ( Figure 1 ).

[0060] (3) Dissolve the sulfated polysaccharide of Porphyra haitanensis (PHSP) in ultrapure water to prepare a 5 mg / mL viscoelastic solution (see Figure 2 A), NP1 was mixed in a volume ratio of 1:1 to obtain a uniform aqueous solution of berberine / basicin nanoparticles (NP1-PHSP) coated with sulfated polysaccharide of Porphyra haitanensis (see Figure 3 A).

[0061] (4) Drop the NP1-PHSP aqueous solution on the conductive resin, vacuum dry it, and apply a gold film using a LEICA-EM-ACE600 sputtering coater. Use SEM (ZEISS-SUPRA55, Germany) to image and observe the morphology of the sample at 10 kV. The results are shown in Figure 2. Figure 4 As shown in A, the dried PHSP is in the form of paper paste, and NP1-PHSP is in the form of irregular particles ( Figure 5 A), the morphology is uniform, and it can be seen that all particles are wrapped and gathered by a layer of paste-like substance, so the edge contour of the particles cannot be clearly observed under the electron microscope.

[0062] Example 2: Preparation and characterization of berberine / basicin complex nanoparticles coated with Eucheuma sulfate polysaccharide

[0063] (1) Prepare berberine and baicalin aqueous solutions with a concentration of 2 mM each.

[0064] (2) A round-bottom flask containing 8.51 mL of baicalin (2 mM, pH = 10.0) and 8.51 mL of berberine (2 mM) was placed on a heat-collecting constant temperature magnetic stirrer at a speed of 20 rpm and heated at 80°C for 1 h. After centrifugation at 9000 r / min, the supernatant was discarded, and the precipitate was washed with ultrapure water for 3 times, and 4.25 mL of ultrapure water was added and mixed. The precipitate was berberine / baicalin complex nanoparticles (NP1). The nanoparticles showed a mesh-like nanofiber structure under a transmission electron microscope, and the diameter of the nanofibers was about 1 nm-50 nm ( Figure 1 ).

[0065] (3) Dissolve Eucheuma sulfate polysaccharide (ESP) in ultrapure water to prepare a 5 mg / mL viscosity solution (see Figure 2 B), NP1 was mixed in a volume ratio of 1:1 to obtain a uniform aqueous solution of berberine / basicin nanoparticles (NP1-ESP) coated with sulfated polysaccharide of Porphyra haitanensis (see Figure 3 B).

[0066] (4) Drop the NP1-PHSP aqueous solution on the conductive resin, vacuum dry it, and apply a gold film using a LEICA-EM-ACE600 sputtering coater. Use SEM (ZEISS-SUPRA55, Germany) to image and observe the morphology of the sample at 10 kV. The results are shown in Figure 2. Figure 4 As shown in B, the dried ESP is in the form of paper paste, and NP1-ESP is in the form of irregular particles ( Figure 5 B), the morphology is uniform, and it can be seen that all particles are wrapped and gathered by a layer of paste-like substance, so the edge contour of the particles cannot be clearly observed under the electron microscope.

[0067] Example 3: Anti-Staphylococcus aureus Experiment

[0068] This example provides the anti-Staphylococcus aureus effect of berberine / baicalin complex nanoparticles (NP1-PHSP) coated with sulfated polysaccharide of Porphyra haitanensis.

[0069] Experimental methods:

[0070] (1) Bacterial dilution: 2 mL of sterile water was filled into a sterile test tube, and a dry cotton swab was moistened. The turbidimeter was cleared with sterile water. A wet cotton swab was used to dip into the standard strain of Staphylococcus aureus (ATCC 29213) that had been tested for quality, and the test tube wall was grinded to disperse the bacterial blocks, and then the cotton swab was immersed in sterile water to mix well; the bacterial concentration was adjusted to 0.58 MCF using a turbidimeter, and the bacterial suspension was diluted 100 times with MH nutrient broth, and mixed well to adjust the bacterial solution concentration to 2 × 10 6 CFU / mL.

[0071] (2) Sample dilution and loading

[0072] Berberine (2 mM, stock solution) gradient dilution: 400 μM, 200 μM, 100 μM, 50 μM;

[0073] 96-well plate loading: 50 μL bacterial solution + 50 μL berberine, berberine final concentration (200 μM, 150 μM, 100 μM, 75 μM, 50 μM, 25 μM);

[0074] NP1 (400 μM, stock solution) gradient dilution: 400 μM, 200 μM, 100 μM, 50 μM;

[0075] 96-well plate loading: 50 μL bacterial solution + 50 μL NP1, final concentration of NP1 (200 μM, 150 μM, 100 μM, 75 μM, 50 μM, 25 μM);

[0076] NP1-PSHP (400 μM, stock solution) serial dilution (400 μM, 200 μM, 100 μM, 50 μM);

[0077] Loading of samples into 96-well plate: 50 μL bacterial solution + 50 μL NP-polysaccharide, NP1-PSHP (200 μM, 150 μM, 100 μM, 75 μM, 50 μM, 25 μM).

[0078] (3) Constant temperature culture

[0079] 35℃, 17h.

[0080] (4) Gradient dilution of the solution after incubation

[0081] Dilution No. 1: 450 μL normal saline + 50 μL post-culture solution, diluted 10 times, i.e. 101 times;

[0082] Diluent No. 2: 450 μL normal saline + 50 μL diluent No. 1, diluted 10 times, i.e. 102 times;

[0083] Diluent No. 3: 10 μL normal saline + 990 μL diluent No. 2, diluted 100 times, i.e. 104 times;

[0084] Dilution No. 4: 10 μL normal saline + 990 μL diluent No. 3, diluted 100 times, that is, diluted 106 times.

[0085] (5) Coating the flat plate

[0086] 100 μL of dilution No. 4 was taken and spread on a plate. After culturing for 20 hours, the inhibitory effect on the standard strain Staphylococcus aureus (ATCC29213) was observed. The results are shown in Table 1.

[0087] Table 1

[0088]

[0089] Example 4: Anti-Salmonella Enteritidis Experiment

[0090] This example provides an anti-Salmonella enteritidis experiment of berberine / baicalin complex nanoparticles (NP1-PHSP) coated with sulfated polysaccharide of Porphyra haitanensis.

[0091] Experimental methods:

[0092] (1) Bacterial dilution: Fill a sterile test tube with 2 mL of sterile water, moisten a dry cotton swab, and clear the turbidimeter with sterile water.

[0093] Use wet cotton swabs to dip into clinical strains of Staphylococcus epidermidis (laboratory number: W2912) that have been quality-checked, grind the tube wall to disperse the bacterial blocks, and then immerse the cotton swabs in sterile water to mix well; use a turbidimeter to adjust the bacterial concentration to 0.54 MCF, use MH nutrient broth to dilute the bacterial suspension 100 times, mix well, and adjust the bacterial solution concentration to 2×10 6 CFU / mL.

[0094] (2) Sample dilution and loading

[0095] Berberine (2 mM, stock solution) dilution: serial dilution (150 μM, 75 μM, 37.5 μM);

[0096] 96-well plate loading: 50 μL bacterial solution + 50 μL berberine, berberine final concentration (75 μM, 37.5 μM, 18.75 μM);

[0097] NP1 (200 μM, stock solution), serial dilution (150 μM, 75 μM, 37.5 μM);

[0098] 96-well plate loading: 50 μL bacterial solution + 50 μL NP1, final concentration of NP1 ((75 μM, 37.5 μM, 18.75 μM);

[0099] NP1-polysaccharide (200 μM, stock solution), serial dilution (150 μM, 75 μM, 37.5 μM);

[0100] Loading of samples into 96-well plate: 50 μL bacterial solution + 50 μL NP-polysaccharide, 1 NP1-polysaccharide (75 μM, 37.5 μM, 18.75 μM).

[0101] (3) Constant temperature culture

[0102] 35℃, 17h.

[0103] (4) Gradient dilution of the solution after culture:

[0104] Dilution No. 1: 450 μL normal saline + 50 μL post-culture solution, diluted 10 times, i.e. 101 times;

[0105] Diluent No. 2: 450 μL normal saline + 50 μL diluent No. 1, diluted 10 times, i.e. 102 times;

[0106] Diluent No. 3: 10 μL normal saline + 990 μL diluent No. 2, diluted 100 times, i.e. 104 times;

[0107] Dilution No. 4: 10 μL normal saline + 990 μL diluent No. 3, diluted 100 times, that is, diluted 106 times.

[0108] (5) Coating the flat plate

[0109] Take 100 μL of dilution No. 4, spread it on the plate, and after culturing for 20 hours, observe the inhibitory effect on Staphylococcus epidermidis. The results are shown in Table 2.

[0110] Table 2

[0111]

[0112] Example 5: Experiment on the antibacterial rate of Shigella flexneri

[0113] This example provides the antibacterial rate of berberine / baicalin complex nanoparticles (NP1-PHSP) coated with sulfated polysaccharide of Porphyra haitanensis against Shigella flexneri.

[0114] Experimental method: (1) Bacterial dilution: 2 mL of sterile water was filled into a sterile test tube, a dry cotton swab was moistened, and the turbidimeter was cleared with sterile water.

[0115] Use wet cotton swabs to dip into the clinical strain Shigella flexneri (laboratory number: QC1412) that has been quality-checked, grind the test tube wall to disperse the bacterial blocks, and then immerse the cotton swabs in sterile water to mix well; use a turbidimeter to adjust the bacterial concentration to 0.60 MCF, use MH nutrient broth to dilute the bacterial suspension 100 times, mix well, and adjust the bacterial solution concentration to 2×10 6 CFU / mL.

[0116] (2) Sample dilution and loading

[0117] Berberine (2 mM, stock solution) dilution: serial dilution (800 μM, 400 μM, 200 μM);

[0118] 96-well plate loading: 50 μL bacterial solution + 50 μL berberine, berberine final concentration (400 μM, 200 μM, 100 μM);

[0119] NP1 (800 μM, stock solution), serial dilution (800 μM, 400 μM, 200 μM);

[0120] 96-well plate loading: 50 μL bacterial solution + 50 μL NP1, NP1 final concentration 400 μM, 200 μM, 100 μM);

[0121] NP1-polysaccharide (800 μM, stock solution), serial dilution (800 μM, 400 μM, 200 μM);

[0122] Loading samples into 96-well plate: 50 μL bacterial solution + 50 μL NP-polysaccharide, NP1-polysaccharide (400 μM, 200 μM, 100 μM).

[0123] (3) Constant temperature culture

[0124] 35℃, 17h.

[0125] (4) Gradient dilution of the solution after incubation

[0126] Dilution No. 1: 450 μL normal saline + 50 μL post-culture solution, diluted 10 times, i.e. 101 times;

[0127] Diluent No. 2: 450 μL normal saline + 50 μL diluent No. 1, diluted 10 times, i.e. 102 times;

[0128] Diluent No. 3: 10 μL normal saline + 990 μL diluent No. 2, diluted 100 times, i.e. 104 times;

[0129] Dilution No. 4: 10 μL normal saline + 990 μL diluent No. 3, diluted 100 times, that is, diluted 106 times.

[0130] (5) Coating the flat plate

[0131] 100 μL of dilution No. 4 was taken and spread on the plate. After culturing for 20 hours, the inhibitory effect on Shigella flexneri was observed. The results are shown in Table 3.

[0132] Table 3

[0133]

[0134] When the final concentration of PHSP was 2 μM, its inhibition rate against Shigella flexneri was only 17.58%.

[0135] The technical solution of the present invention is not limited to the above-mentioned specific embodiments. All technical variations made according to the technical solution of the present invention fall within the protection scope of the present invention.

Claims

1. Use of a composition with antibacterial activity in the preparation of an anti-Staphylococcus epidermidis and / or Shigella flexneri medicament, the composition comprising: (1) sulfated polysaccharides, and (2) Complex of isoquinoline alkaloids and flavonoid glycosides, The sulfated polysaccharide encapsulates the complex; the isoquinoline alkaloid is selected from berberine or its salt; the flavonoid glycoside is selected from baicalin and melaleuca; the sulfated polysaccharide is a sulfated polysaccharide of red algae, and the red algae is selected from Porphyra haitanensis, Gracilaria lemaneiformis and Eucheuma; The preparation method of the composition comprises the following steps: (1) mixing the sulfated polysaccharide with a first solvent to form a sulfated polysaccharide solution; (2) mixing the complex of isoquinoline alkaloid and flavonoid glycoside with a second solvent to form a complex solution of isoquinoline alkaloid and flavonoid glycoside; (3) mixing the sulfated polysaccharide solution with the complex solution of isoquinoline alkaloid and flavonoid glycoside; The concentration of the sulfated polysaccharide solution is 5 mg / mL-15 mg / mL; the concentration of the complex solution of isoquinoline alkaloids and flavonoid glycosides is 2 mmol / L-10 mmol / L; the volume ratio of the sulfated polysaccharide solution to the complex solution of isoquinoline alkaloids and flavonoid glycosides is (1-3):

1.

2. The use according to claim 1, characterized in that: The composite has a nanostructure.

3. The use according to claim 1, characterized in that: The complex is a nanocomposite of berberine and baicalin.

4. The use according to claim 1, characterized in that: The composite is prepared by a method comprising the following steps: (1) dissolving an isoquinoline alkaloid in solvent A to obtain an isoquinoline alkaloid solution; (2) dissolving the flavonoid glycoside in solvent B to obtain a flavonoid glycoside solution; (3) The isoquinoline alkaloid solution and the flavonoid glycoside solution are mixed to obtain a complex of the isoquinoline alkaloid and the flavonoid glycoside.

5. The use according to claim 1, characterized in that: The dosage form of the drug is tablet, powder, granule, ointment, cream or capsule.